Virologica Sinica

, Volume 33, Issue 4, pp 369–372 | Cite as

KIR2DL2/C1 is a Risk Factor for Chronic Infection and Associated with Non-response to PEG-IFN and RBV Combination Therapy in Hepatitis C Virus Genotype 1b Patients in China

  • Song Hu
  • Fahu Yuan
  • Lingyan Feng
  • Fang Zheng
  • Feili Gong
  • Hanju Huang
  • Binlian Sun

Dear Editor,

Natural killer (NK) cells are lymphocytes that play important roles in the host defense against hepatitis C virus (HCV) infection. Killer cell immunoglobulin-like receptors (KIRs) are a group of regulatory molecules expressed on NK cells and a subset of T cells (Parham 2005). Ligands for KIRs are human leukocyte antigen (HLA) class I molecules, and HLA-C1 is a ligand for the inhibitory receptors KIR2DL2, KIR2DL3 and the activating receptor KIR2DS2 (Robinson et al.2003; Du et al.2007). In 2002, the National Institutes of Health Consensus Development Conference concluded that a combination therapy of pegylated alpha interferon (PEG-IFN) with ribavirin (RBV) manages HCV infections effectively (Gebo and Bartlett 2002). Before the direct-acting antiviral agent treatment was approved, PEG-IFN and RBV were the main antiviral treatments for chronic HCV in China (Chinese Society of Hepatology et al.2015). Patients that receive the same standard combination therapies are classified...



We thank all subjects who donated samples for this study. This work was supported by Grants from the National Major Science and Technology Project for Infectious Diseases of China (2012ZX10004503), and Major State Basic Research Development Program of China (973 Program; No. 2013CB530505).

Compliance with Ethical Standards

Conflict of interest

The authors declare that they have no conflicts of interest.

Animal and Human Rights Statement

This study conformed to the 1975 Declaration of Helsinki guidelines and permission was obtained from the Ethics Committee of Tongji Medical College, Huazhong University of Science and Technology. Prior to the study, informed consent was obtained from each individual.

Supplementary material

12250_2018_42_MOESM1_ESM.pdf (437 kb)
Supplementary material 1 (PDF 438 kb)


  1. Asselah T (2012) A revolution in hcv treatment with direct-acting antivirals: from non-response to eradication. J Hepatol 57:455–457CrossRefPubMedGoogle Scholar
  2. Bashirova AA, Martin MP, McVicar DW, Carrington M (2006) The killer immunoglobulin-like receptor gene cluster: tuning the genome for defense. Annu Rev Genomics Hum Genet 7:277–300CrossRefPubMedGoogle Scholar
  3. Bunce M, O’Neill CM, Barnardo MC, Krausa P, Browning MJ, Morris PJ, Welsh KI (1995) Phototyping: comprehensive DNA typing for HLA-A, B, C, DRB1, DRB3, DRB4, DRB5 & DQB1 by PCR with 144 primer mixes utilizing sequence-specific primers (PCR-SSP). Tissue Antigens 46:355–367CrossRefPubMedGoogle Scholar
  4. Carneiro VL, Lemaire DC, Bendicho MT, Souza SL, Cavalcante LN, Angelo AL, Freire SM, Mendes CM, Santana N, Lyra LG, Lyra AC (2010) Natural killer cell receptor and HLA-C gene polymorphisms among patients with hepatitis C: a comparison between sustained virological responders and non-responders. Liver Int 30:567–573CrossRefPubMedGoogle Scholar
  5. Chinese Society of Hepatology CMA, Wei L, Chinese Society of Infectious Diseases CMA, Hou JL (2015) The guideline of prevention and treatment for hepatitis C: a 2015 update. Zhonghua Gan Zang Bing Za Zhi 23:906–923Google Scholar
  6. de Vasconcelos JM, de Jesus Maues Pereira Moia L, Amaral IS, Miranda EC, Cicalisetakeshita LY, de Oliveira LF, de Araujo Melo Mendes L, Sastre D, Tamegao-Lopes BP, de Aquino Pedroza LS, Batista Dos Santos SE, Soares MC, de Araujo MT, Bandeira CL, de Sousa da Silva AM, de Medeiros ZL, Sena L, Demachki S, Dos Santos EJ (2013) Association of killer cell immunoglobulin-like receptor polymorphisms with chronic hepatitis c and responses to therapy in Brazil. Genet Mol Biol 36:22–27CrossRefPubMedPubMedCentralGoogle Scholar
  7. Dring MM, Morrison MH, McSharry BP, Guinan KJ, Hagan R, Irish HCVRC, O’Farrelly C, Gardiner CM (2011) Innate immune genes synergize to predict increased risk of chronic disease in hepatitis C virus infection. Proc Natl Acad Sci U S A 108:5736–5741CrossRefPubMedPubMedCentralGoogle Scholar
  8. Du Z, Gjertson DW, Reed EF, Rajalingam R (2007) Receptor-ligand analyses define minimal killer cell ig-like receptor (KIR) in humans. Immunogenetics 59:1–15CrossRefPubMedGoogle Scholar
  9. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347:975–982CrossRefPubMedGoogle Scholar
  10. Gebo KA, Bartlett JG (2002) Management of hepatitis C: a review of the NIH consensus development conference. Hopkins HIV Rep 14:1–4Google Scholar
  11. Hsu KC, Liu XR, Selvakumar A, Mickelson E, O’Reilly RJ, Dupont B (2002) Killer ig-like receptor haplotype analysis by gene content: evidence for genomic diversity with a minimum of six basic framework haplotypes, each with multiple subsets. J Immunol 169:5118–5129CrossRefPubMedGoogle Scholar
  12. Parham P (2005) MHC class I molecules and KIRs in human history, health and survival. Nat Rev Immunol 5:201–214CrossRefPubMedGoogle Scholar
  13. Robinson J, Waller MJ, Parham P, de Groot N, Bontrop R, Kennedy LJ, Stoehr P, Marsh SG (2003) IMGT/HLA and IMGT/MHC: sequence databases for the study of the major histocompatibility complex. Nucleic Acids Res 31:311–314CrossRefPubMedPubMedCentralGoogle Scholar
  14. Single RM, Martin MP, Gao X, Meyer D, Yeager M, Kidd JR, Kidd KK, Carrington M (2007) Global diversity and evidence for coevolution of KIR and HLA. Nat Genet 39:1114–1119CrossRefPubMedGoogle Scholar
  15. Vidal-Castineira JR, Lopez-Vazquez A, Diaz-Pena R, Alonso-Arias R, Martinez-Borra J, Perez R, Fernandez-Suarez J, Melon S, Prieto J, Rodrigo L, Lopez-Larrea C (2010) Effect of killer immunoglobulin-like receptors in the response to combined treatment in patients with chronic hepatitis C virus infection. J Virol 84:475–481CrossRefPubMedGoogle Scholar
  16. Vidal-Castineira JR, Lopez-Vazquez A, Martinez-Borra J, Martinez-Camblor P, Prieto J, Lopez-Rodriguez R, Sanz-Cameno P, de la Vega J, Rodrigo L, Perez-Lopez R, Perez-Alvarez R, Lopez-Larrea C (2014) Diversity of killer cell immunoglobulin-like receptor (KIR) genotypes and KIR2DL2/3 variants in HCV treatment outcome. PLoS ONE 9:e99426CrossRefPubMedPubMedCentralGoogle Scholar
  17. Zwolinska K, Blachowicz O, Tomczyk T, Knysz B, Gasiorowski J, Zalewska M, Orzechowska BU, Sochocka M, Piasecki E (2016) The effects of killer cell immunoglobulin-like receptor (KIR) genes on susceptibility to HIV-1 infection in the polish population. Immunogenetics 68:327–337CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Wuhan Institute of Virology, CAS and Springer Nature Singapore Pte Ltd. 2018

Authors and Affiliations

  1. 1.Medical CollegeJianghan UniversityWuhanChina
  2. 2.Department of Immunology, School of Basic Medicine, Tongji Medical CollegeHuazhong University of Science and TechnologyWuhanChina
  3. 3.Department of Pathogen Biology, Tongji Medical CollegeHuazhong University of Science and TechnologyWuhanChina

Personalised recommendations